• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

EMA gives positive opinion on Novo Nordisk’s human insulin with flexible storage

April 25, 2022 By Sean Whooley

Novo Nordisk
Novo Nordisk

Novo Nordisk (NYSE:NVO) announced that the European Medicines Agency (EMA) granted a positive opinion on a storage update for insulin.

EMA’s positive opinion relates to a proposed update to the storage conditions of two human insulins: Actrapid (short-acting insulin) and Insulatard (intermediate-acting insulin).

Bagsværd, Denmark-based Novo Nordisk said in a news release that the EMA’s positive opinion will be used to support obtaining approval of the more flexible storage conditions by national health authorities in several low- and middle-income countries.

The company seeks approval for Actrapid and Insulatard to be stored for four weeks outside of a refrigerator (if kept below 30° C) prior to use if there are six months or more to the expiry date. Once in use, the insulin should be stored without refrigeration.

Novo Nordisk said this flexibility aims to improve the convenience for many people with diabetes in low- and middle-income countries who have limited access to reliable refrigeration and who may live within long distances from a clinic or pharmacy.

“I am proud of our continuous efforts to innovate and adapt to improve access to life-saving medicines for people living with serious chronic diseases,” Novo Nordisk EVP of Development Martin Holst Lange said in the release. “The EMA positive opinion paves the way for us to start updating the label for two human insulin products in low- and middle-income countries, to allow patients to store their insulin outside of the refrigerator for one month before use. Looking ahead, we hope to be able to develop an actual thermostable insulin but until then, we will continue to pursue other means of addressing this barrier.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Regulatory/Compliance Tagged With: Novo Nordisk

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS